Close

Industry Reports

Pfizer reports second-quarter 2012 results

Pfizer Inc. reported financial results for second-quarter 2012. Second-quarter 2012 revenues were $15.1 billion, a decrease of 9% compared with $16.5 billion in the year-ago quarter, which reflects an operational decline of $977 million, or 6%, and the...

Amgen’s second quarter 2012 revenues increased 13 percent to $4.5 billion

Amgen announced financial results for the second quarter of 2012. Key results for the quarter include: Total revenues increased 13 percent to $4,477 million, with 8 percent product sales growth driven by strong performance across the portfolio; Amgen...

Novartis second quarter results enhance future growth prospects

Group net sales reached USD 14.3 billion (-4%, +1% cc) in the second quarter, with growth from recently launched products more than offsetting the loss associated with the Diovan patent expiration. Currency had a negative impact of 5...

Abbott reports strong second quarter results

Abbott announced financial results for the second quarter ended June 30, 2012. Diluted earnings per share, excluding specified items, were $1.23, reflecting 9.8 percent growth, exceeding Abbott's guidance range. Diluted earnings per share under Generally Accepted Accounting Principles...

Ironwood Pharmaceuticals Provides Second Quarter 2012 Investor Update Ironwood Pharmaceuticals Inc.

Ironwood Pharmaceuticals, Inc. today provided an update on its second quarter 2012 and recent business activities. Second Quarter 2012 and Recent Highlights Linaclotide In April, the U.S. Food and Drug Administration (FDA) notified Ironwood...

Merck total revenues increase 3.2% to € 2.6 billion

The Merck Group's first-quarter 2012 total revenues rose 3.2% to € 2,645 million compared to € 2,564 million in the first quarter of 2011. Sales for the Group increased 3.5% to € 2,564 million in first quarter compared...

Infinity Reports First Quarter 2012 Financial Results

Infinity Pharmaceuticals, Inc.today reported its financial results for the first quarter of 2012. The company maintained its strong financial condition while continuing to advance its clinical programs during the quarter toward the key development milestones expected in the...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Must read